Clinical Trials on Microsatellite Instability-high (MSI-H) in China
Total 34 results
-
LiuYingNot yet recruitingColorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingColorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Sun Yat-sen UniversityRecruitingColorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Sun Yat-sen UniversityRecruitingColorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Sun Yat-sen UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...Active, not recruitingColorectal Cancer | Microsatellite Instability HighChina
-
Sun Yat-sen UniversityThe Second Affiliated Hospital of Kunming Medical UniversityCompletedColorectal Cancer Metastatic | Microsatellite Instability High | Mismatch Repair DeficiencyChina
-
AkesoAkeso Pharmaceuticals, Inc.TerminatedMSI-H/dMMR Solid TumorChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownMSI-H or dMMR Advanced Solid TumorsChina
-
BeiGeneRecruitingMSI-H/dMMR Solid TumorsChina
-
Changhai HospitalRecruitingRectal Cancer | Microsatellite Instability Low | Immunotherapy | Neoadjuvant Chemoradiation TherapyChina
-
Shanghai Henlius BiotechRecruiting
-
Peking University Cancer Hospital & InstituteRecruiting
-
Shanghai Minimally Invasive Surgery CenterUnknown
-
Affiliated Hospital of Qinghai UniversityLanZhou University; Qinghai People's HospitalCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruiting
-
Anhui Provincial HospitalNot yet recruitingHigh Titers of Anti-HLA Antibody (MFI ≥5000)China
-
Fudan UniversityNot yet recruitingGastric Cancer | MSI-H | Adjuvant Therapy | PD-1 ImmunotherapyChina
-
Tianjin Medical University Cancer Institute and...RecruitingColon Cancer | Immunotherapy | MSI-H | Adjuvant TherapyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Tianjin Medical University Cancer Institute and...RecruitingMSI-H Advanced Colorectal CancerChina
-
Sun Yat-sen UniversityActive, not recruitingDMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal CancerChina
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaboratorsRecruitingRectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr DeficiencyChina
-
Shen LinNot yet recruitingTo Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal CancerChina
-
Sun Yat-sen UniversityRecruitingColorectal Cancer Stage II | Colorectal Cancer Stage III | MSI-H | Mmr DeficiencyChina
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdRecruitingMetastatic Colorectal CancerUnited States, Belgium, China, Canada, Denmark, France, Norway, Romania, Spain, United Kingdom, Austria, Brazil, Germany, Netherlands, Argentina, Czechia, Ireland, Italy, Turkey, Chile, Greece, Puerto Rico, Australia, Japan
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Novartis PharmaceuticalsRecruitingMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersJapan, Italy, Spain, Singapore, Belgium, Germany, Korea, Republic of, Taiwan, France, Israel, Norway, United States
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Lei LiUnknownLynch Syndrome | Endometrial Cancer | Microsatellite Instability | Circulating Tumor CellChina
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHRecruitingLiver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal CancerChina
-
Nanfang Hospital, Southern Medical UniversityShanghai Junshi Bioscience Co., Ltd.RecruitingRectal Cancer | MSS | Locally Advanced | High-RiskChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | High-grade Serous Ovarian Carcinoma | Survival Outcomes | Overall Survival | Progression-free Survival | Chromosomal Instability | Somatic Copy Number Distortion | Minimal Residual LesionsChina
-
Zhujiang HospitalRecruitingHigh Grade Glioma | Radiation Toxicity | Overall Survival | Progression-free Survival | MRI Simulated PositioningChina
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)France, United States, Japan, Belgium, Australia